Los Angeles: Pfizer has indicated that recent clinical trials of inhaled insulin has received the approval from the drug regulators and is found to be useful in regulating blood sugar levels spanning a 2 year period.
This product, named Exubera, is slated to be introduced into the United States market soon after the U.S. Food and Drug Administration approves it for use in adults with Type 1 or Type 2 diabetes.
Dr. Julio Rosenstock, trial investigator and director of the Dallas Diabetes & Endocrine Center said "There are a lot of physical barriers to injected insulin. This (Exubera) is a good tool to facilitate initiation of insulin treatment."
For those sufferings Type 2 diabetes, Exubera is permissible either alone or in combination with diabetes medication or longer-acting insulin. For type 1 diabetics, Exubera is advised to be combined with longer-acting insulin. This drug is not to be consumed by smokers, patients with lung problems and expecting women.